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EU Action Plan on Drugs 2021-2025 
 
A) ENHANCED SECURITY - DISRUPTING THE DRUG MARKETS 
Strategic priority 1. Disrupt and dismantle major high-risk drug-related organised crime groups operating in, originating in or targeting the EU 
Member States and address links with other security threats  
Actions  Corresponding 
priority area 
Timetable Responsibility  
Action 1. Further enhance: (i) the EU policy cycle for organised and serious international 
crime (EMPACT) on the basis of its 2020 evaluation and by taking into account the 
SOCTA
1
 2021; (ii) the findings and recommendations from the annual European Drug 
Reports by the EMCDDA
2
 and the EU Drug Markets Report by the EMCDDA and 
Europol; and (iii) in line with the lessons learned from the impact of the COVID-19 
pandemic on drug markets. Increase coordination and cooperation to achieve more tangible 
investigative results, including through EMPACT, as well as increased exchange of 
information on drug-related organised crime groups, domestic and international, and 
increased use of the Secure Information Exchange Network Application (SIENA).  




Action 2: Reinforce information sharing and analysis on the relationship between drug 
markets related criminality (production, trafficking and distribution) and (i) other forms of 
serious crime, including trafficking in human beings, migrant smuggling, trafficking of 
firearms and terrorism; (ii) enabling forms of serious crime including drug related 
violence/homicide, corruption and money laundering.  
1.1 
1.2 




                                                          
1
  Serious and Organised Crime Threat Assessment. 
2






Action 3. Prioritise investigations on drug related organised crime groups and networks 
posing the highest security risk in the EU through a high-value target selection process 
established by the Member States with the support of Europol. An integral part of such 
investigations should be asset-tracing and financial investigations to lead to the effective 
confiscation of proceeds of drug crimes. Ensure increased cooperation and coordination of 
operational activities within EU and between Member States, relevant third countries and 
Europol; also increase cooperation with Eurojust on related judicial prosecution.  
1.1 
1.2 
2021-2025 European Commission  





Action 4. Ensure that Member States give law enforcement authorities swift access to 
financial information to allow them to carry out effective financial investigations of drug 
related organised crime groups, including by: (i) Make full use of information held by 
Financial Intelligence Units (FIUs) under the conditions laid out by the Directive on the 
use of financial information (Directive (EU) 2019/1153). (ii) Make more effective use of 
information gathered by Asset Recovery Offices to identify and track profits linked to drug 
trafficking, with a view to their possible subsequent freezing and confiscation. Increase 
training for law enforcement and judicial investigators and the local and regional 
specialised units dedicated to the seizures of criminal assets.  





Action 5. Increase the cooperation and establish better links between tax/customs 
authorities and law enforcement in order to (i) enhance investigations, (ii) detect trade 
based money-laundering activities, (iii) disrupt criminal activities and (iv) stop profits from 
drug markets going back into furthering criminal activities or into the legal economy. 
Member States are encouraged to build their expertise and resources on alternative banking 
and money transfer systems used by drug related organised crime groups (e.g. Hawala). 





Action 6. Identify and prioritise cooperation with high-risk countries from drug production 
and smuggling perspective in order to (i) facilitate Member States’ access to financial and 





other information to strengthen the capacity of the competent authorities to conduct 
financial investigations, and (ii) trace and identify drugs-related criminal proceeds and 
ensure that EU based seizure and confiscation orders are executed. 
Europol  
Eurojust 
Action 7. Consider how to further tackle encryption and other new technology-related 
methods employed by organised crime groups active in the drug markets to avoid detection 
and hide their communications. Increase sharing in real-time of actionable and 
prosecutable information within and between Member States, Europol and Eurojust.  





Action 8. Following the effective confiscation of assets, take under consideration the safe 
and secure reuse of seized and confiscated instrumentalities in support of drug demand and 
supply reduction measures. The European Commission will further consider this point 
within the scope of the possible revision of the Directive on the freezing and confiscation 
of instrumentalities and proceeds of crime in the European Union (Directive 2014/42/EU). 
1.2 2021-2025 European Commission  
Member States 
 
Action 9. Ensure that relevant EU cooperation programmes on drugs worldwide are in 
place and implemented with third countries and regions. Increase the joint strategic and 
operational analysis (i) by involving relevant EU agencies such as EMCDDA and Europol 
and (ii) by ensuring regular and timely reporting of relevant and operational information 
between cooperation programmes and these EU agencies.  




Action 10. Improve EU dialogues on drugs that focus on specific drug trafficking routes, 
involving producer, transit and consumer markets. Regular dialogues should be conducted 
with the Western Balkan region and countries, Eastern Partnership countries, Central Asia 
region and countries, Russia, USA, Latin America and the Caribbean regions and 
countries. In addition, dialogues on drugs should be launched with China, Iran and 
Colombia. Further dialogues with other countries or regions will be explored depending on 
the evolution of the drug supply origin and routes and international developments.  






Strategic priority 2. Increase detection of illicit wholesale trafficking of drugs and drug precursors at EU points of entry and exit 
Actions  Corresponding 
priority area 
Timetable Responsibility  
Action 11. Support activities in major drug trafficking entry and exit points by reinforcing 
and promoting the establishment of customs risk analysis, investigation methods, and other 
relevant policies, controls and procedures to combat drug trafficking. Ensure structured 
coordination and cooperation as well as exchange in real time of crime intelligence and 
coordinated investigations in the EU by using the services of relevant EU agencies such as 
Europol and Frontex to support Member States. Furthermore, the secure communication 
application of the World Customs Organization should be enabled to exchange information 
with SIENA via a system-to-system communication. 




Action 12. Support Member States in the development of effective screening technologies 
capable of detecting drugs and drug precursors for containers, trucks, ships, focusing on 
major ports, airports, train stations and major land border crossings. 




Action 13. Improve structured coordination and cooperation between customs and Frontex, 
Europol and EMCDDA, as well as exchange of customs information to be interoperable 
and combined with that of law enforcement and border control. Increase the number of 
custom experts within Europol, and reinforce the capability of Frontex border guards to 
detect drug trafficking at EU’s borders.  






Action 14. Establish the necessary link and cooperation with the relevant civil aviation and 
maritime authorities in order to ensure effective and efficient investigations and detection 
of drugs at airports and ports. Strengthen international cooperation with maritime and civil 
2.1 
2.2 






aviation authorities in key partner countries along major drug trafficking routes. EEAS 
 
Action 15. Continue financing and providing the Maritime Analysis and Operation Centre 
- Narcotics (MAOC-N) with a sustainable long-term governance model. Ensure exchange 
of information and cooperation with the relevant EU agencies. 






Action 16. Establish a joint drug intelligence fusion platform within Europol that includes 
Member States representatives, and has contact points with secured information exchange 
capacities in third countries and regions constituting drug trafficking hubs. Ensure 
exchange of intelligence in real time, analysis and support to live operations targeting 
international drug trafficking organised crime groups affecting the EU. 





Action 17. Conclude agreements between the European Union  and third countries where 
drug trafficking hubs are located, enabling relevant EU agencies such as Europol and 
Frontex to exchange information and data, including personal and operational data.  
2.2 2021 European Commission  
 
Strategic priority 3. Increase effective monitoring of logistical and digital channels exploited for medium and small-volume drug distribution 
and increase seizures of illicit substances smuggled through these channels in close cooperation with the private sector   
Actions  Corresponding 
priority area 
Timetable Responsibility  
Action 18. Monitor internet and darknet market places for drugs by implementing the 
preparatory action proposed by the European Parliament on 24/7 monitoring of the darknet 




to ensure comprehensive results.
3




Action 19. Operational feasibility analysis of how postal and express services can detect 
and prevent distribution of illicit substances in postal items
4
. Conclude Memoranda of 
Understanding with the objective to enhance cooperation between law enforcement, 
customs, postal and express services and electronic payment providers. 
3.2 2021-2025 European Commission  




Action 20. Promote the development, use and exchange of best practices and equipment 
among Member States on monitoring of suspicious postal items by employing solutions 
such as detection dogs and/or x-ray machines. Notably, the role of new technologies and 
especially of artificial intelligence should be examined.  
3.2 2021-2025 European Commission 
Member States 
 
Action 21. Raise awareness for the need to focus actions on drug trafficking channels 
currently insufficiently monitored by law enforcement, by establishing or reinforcing 
monitoring and investigation methods of smaller sea harbours and fluvial ports, airfields, 
and train stations. Involve relevant EU agencies to support Member States in these 
activities. 





Strategic priority 4. Dismantle drug production and processing, prevent the diversion and trafficking of drug precursors for illicit drug 
production, and eradicate illegal cultivation 
Actions  Corresponding Timetable Responsibility  
                                                          
3
  For details, see Item 18 02 77 04 — Preparatory action — EU-coordinated Darknet monitoring to counter criminal activities, provided on page 61 of Annex 3 PP/PA budgetary 
remarks.  
4
  Postal item: an item addressed in the final form in which it is to be carried by a postal service provider. In addition to items of correspondence, such items also include for instance 





Action 22. Boost the operational activities of law enforcement and their cooperation with 
administrative authorities and other relevant parties with regard to the fight against 
environmental crime related to illicit drug production and trafficking. Develop detection 
technologies, information exchange and coordinated investigations by involving relevant 








Action 23. Address the main challenges identified by the evaluation of the drug precursor 
legislation, in particular the need to address the challenge posed by designer-precursors.  
4.1 2021 European Commission 
Member States 
Action 24. Identify, track and dismantle illicit drug producing facilities in the EU, 
including by targeting precursors and designer-precursors, by improving and making better 
use of forensic investigations, intelligence and by developing and expanding detection 
techniques.   




Action 25. Consider launching a study assessing the effectiveness of Council Framework 
Decision 2004/757/JHA of 25 October 2004 laying down minimum provisions on the 
constituent elements of criminal acts and penalties in the field of illicit drug trafficking, in 
view of amending possibly outdated aspects and strengthening areas as needed.   
4.1 2022 European Commission 
 
Action 26. Continue supporting and tracking the results of alternative development 
programmes and related development-centred drug policy interventions in source countries 
of illicit drugs, including through the exchange of best practices and technical expertise, 
peer-to-peer learning, and through engagement at global level and with international 
organisations. 
4.2 2021-2025 European Commission 
Member States  
EEAS 
 




Strategic priority 5. Prevent the uptake of drugs, enhance crime prevention, and raise awareness of the adverse effects of drugs on citizens and 
communities  
Actions  Corresponding 
priority area 
Timetable Responsibility  
Action 27. Cross-EU campaigns targeted at parents, teachers and local decision makers, 
raising their awareness of their potential in preventing young people and other targeted 




2021-2025 European Commission 
Member States  
EMCDDA 
 
Action 28. Wider roll-out of the European Prevention Curriculum (EUPC) training 
courses and update to the handbook if needed.  
5.1. 2022-2025 Member States 
EMCDDA 
 
Action 29. Expansion of the section on prevention models and other practical and reliable 
information in the area of prevention, available on the EMCDDA Best Practice Portal and 
encourage the wider adoption of prevention programs with what have been shown to be 
effective.  
5.1 2022-2025 Member States 
EMCDDA 
 
Action 30. Roll-out of targeted rapid alert risk communications and intelligence 
notifications when dangerous substances, including new psychoactive substances (NPS), 
or other emerging threats appear on the market.  
5.1 2021-2025 EMCDDA 
Europol 
Action 31. (i) Promote and support the work and best practices of the European Crime 
Prevention Network (EUCPN) and other relevant projects in view of reducing recidivism 
for young offenders of drug-related crime; (ii) encourage comprehensive strategies to deal 
with neighbourhoods that experience high-levels of drugs and drug related crime and (iii) 
support measures that create a more protective environment for communities affected by 
the consumption and sale of drugs or drug related crime. 







C) ADDRESSING DRUG-RELATED HARMS  
Strategic priority 6. Enhance access to treatment options that meet the range of health and rehabilitation needs of people who experience harm 
from substance use 
Actions  Corresponding 
priority area 
Timetable Responsibility  
Action 32. Develop and enhance the access to effective drug treatment, harm reduction 
and rehabilitation services, including services for people with co-morbidity, to (i) reduce 
the use of illicit drugs and new psychoactive substances (NPS); (ii) problem drug use; (iii) 
the prevalence of drug dependency and drug-related health and social risks and harms and 









Action 33. (i) Support innovation in treatment delivery; (ii) improve and promote the use 
of electronic and mobile health delivery options and new pharmacotherapies in order to 
increase access to drug treatment for all target groups; and, (iii) assess effectiveness of 
such solutions with the possibility of scaling up those interventions that have been shown 










Action 34. Identify the gender physiology of drug addiction. Identify and reduce barriers 
to treatment and other service utilisation for women who use drugs, and enhance treatment 
options to include gender specific approaches. Ensure such services are sensitive to the 
needs of women e.g. include childcare support. Launch outreach efforts to reach women 
drug users and make them aware of available women-focused treatment.  




Action 35. Extend the evidence base in treatment delivery including an improved 
understanding of the scale and trends in problem use of stimulants and cannabis. Also to 









interventions when responding to stimulant or cannabis-related problems. European Medicine 
Agency 
Action 36. Provide the multidisciplinary treatment workforce (staff working in specialist 
services and those dealing with drug issues in generic health or social support services) 
with updated competencies that reflect the changing needs of the target population and 
new developments in our understanding of what constitutes effective care. (i) Encourage 
the sharing of best practices in terms of both basic and specialist skills; (ii) support the 
establishment of quality standards in training; (iii) encourage partnerships between 





2021-2025 Member States 
EMCDDA 
 
Action 37. Continue and further develop the implementation of the EU minimum quality 
standards adopted by the Council in 2015
5
 and evidence-based guidelines into national 









Strategic priority 7. Increase the efficiency of risk and harm reduction interventions to protect the health of drug users and the public 
Actions  Corresponding 
priority area 
Timetable Responsibility  
Action 38. Develop, scale up, and enhance access to effective harm reduction measures. 
Further extend the exchange of best practices in this area among Member States, and with 
partners such as third countries, regions and international organisations. 
7.1 
7.3 
2021 European Commission 
Member States  
EMCDDA 
Action 39. Improve and increase the ability to identify, assess and respond at Member 7.1 2021 European Commission 
                                                          
5





States and EU levels, including through cooperation with European Centre for Disease 
Prevention and Control (ECDC) and via the EU Early Warning System, to epidemic 
outbreaks as well as important behavioural changes in drug use and new psychoactive 




Action 40. Encourage and support research and innovation on drug detection tools to 
prevent drug impaired driving. 
7.4 2021-2025 European Commission 
Member States 
EMCDDA 
Action 41. Determine possible policy options in the context of driving under the influence 
of drugs, including assessing whether to include considerations on drugs in the EU 
Recommendation on permitted blood alcohol content for drivers.  
7.4 2022 European Commission 
Action 42. Scale up the availability, effective implementation, monitoring and evaluation 
of measures provided as an alternative to coercive sanctions for drug using offenders, such 
as (suspension of sentence with) treatment, rehabilitation and recovery, and social 
reintegration. Follow-up to the Study on alternatives to coercive sanctions as response to 
drug law offences and drug related crimes concluded in 2016, such as e.g. through a 
possible Commission Recommendation on the topic. Include this dimension in the 
political dialogue and cooperation with partner countries. 




Action 43. Introduce and enhance measures to reduce fatal and non-fatal overdoses. 
Including increasing availability, use and access at the community level of opioid 
antagonists (Naloxone) and other harm reduction and policy measures and support the 
evaluation of effective approaches and the exchange of best practices in this area.   
7.2 
7.6 
2021 Member States 
EMCDDA  
Action 44. Strengthen efforts to share forensic and toxicological data: (i) enhance 
analytical methods, test and promote new techniques; (ii) exchange best practices and 
develop joint trainings; (iii) increase cooperation with the Commission's Joint Research 
Centre and the EMCDDA, and through existing networks, such as the Drugs Working 
Group of the European Network of Forensic Science Institutes and the Customs 
Laboratories European Network. Develop and recommend for implementation a set of 







European forensic toxicology guidelines for drug-related death investigations.  
 
Strategic priority 8. Develop a balanced and comprehensive approach to the use of drugs in prisons (reduce demand and restrict supply) 
Actions  Corresponding 
priority area 
Timetable Responsibility  
Action 45. Provide guidelines for Member States to facilitate the development of a 
balanced and comprehensive policy response to the use of drugs in prisons.  
8.1 
8.2 
2024 European Commission 
EMCDDA 
 
Action 46. Implement trainings for prison staff to better detect drugs entering prisons, 
increase awareness of the issue, and implement evidence-based health related drug 
responses within the prison environment. 






Governance, implementation and monitoring of the EU Agenda on Drugs 
Actions  Timetable Responsibility  
Action 47. Enhance monitoring, data collection, research analysis and reporting, and 
provide comprehensive analyses of relevance to the EU drug situation and the EU drug 
markets, including new challenges around international policy developments in both the 
licit and illicit areas in respect to cannabis. (i) Reinforce EMCDDA and its analytical 
capacity including in terms of new and innovative technologies and methods. (ii) Promote 
evidence-based evaluations of policies and interventions at national, EU and international 
levels. (iii) Provide adequate support for the EMCDDA’s Reitox network of National 







Focal Points both in the areas of public health and security, including the Early Warning 
System. 
Action 48. Strengthen responses and improve preparedness to possible future challenges 
by identifying the lessons learnt from the Covid-19 pandemic and by monitoring its short, 
medium and long term impact on service delivery, drug markets, patterns of use and their 
associated harms. 




Action 49. Promote and strengthen dialogue with and involvement of civil society in 
implementation, evaluation and providing input to the development of drug policies at 
Member State, EU and international levels. 
Ongoing  European Commission  
Member States 
Civil Society Forum on 
Drugs 
Action 50. Contribute to shaping the international agenda on drugs policy in line with the 
approach and objectives of the EU Agenda on Drugs, including by accelerating the 
implementation of joint multilateral commitments such as the 2016 Outcome Document of 
the Special Session of the UN General Assembly on the World Drug Problem and in the 
context of the mid-term review of the Ministerial Declaration of the Commission on 
Narcotic Drugs in 2024. 
Ongoing European Commission 
EEAS 
Action 51. Ensure that the protection and promotion of human rights are fully integrated 
in the EU’s relations with, and external assistance to, third countries, regions and 
international organisations. In particular, the EU is strongly and unequivocally opposed to 
the death penalty in all circumstances, including for drug-related offences. 
Ongoing European Commission 
EEAS 




2021 European Commission 
Action 53. Launch an evaluation of the EU Agenda and Action Plan on Drugs.  2024 European Commission 
                                                          
6
  For more, see Drugs and drug addiction – expanding the mandate of the European monitoring centre: https://ec.europa.eu/info/law/better-regulation/have-your-







Performance indicator 1. Drug-related organized crime and gang violence (Europol, 
EMCDDA Drug Related Homicide data/indicator and studies on gang related violence 
and intimidation and involvement of organised crime) 
Performance indicator 2. Emerging threats based on data from timely and forward 
looking sources (where available) including levels of drug volumes consumed in 
community/cities from waste water analysis from those cities currently participating in 
this exercise. (Composite EMCDDA European level indicator based on EMCDDA 
reporting and barometer; SCORE group and EMCDDA; emergency room data; and 
targeted studies) 
Performance indicator 3. Trends in asset recovery and number of financial 
investigations conducted that were triggered based on drug related crimes. (Europol, 
EMCDDA and targeted sources) 
Performance indicator 4. Trends in number of and quantities of seized illicit drugs, new 
psychoactive substances (NPS) and precursor chemicals – indicator should make a clear 
distinction between small and large seizures (EMCDDA and Europol Drug Seizure data 
per substance: cannabis including herbal cannabis, heroin, cocaine, crack cocaine, 
amphetamine, methamphetamine, MDMA, and new psychoactive substances; European 
Commission, EMCDDA and Europol on precursors)  
Performance indicator 5. Early Warning System on new psychoactive substances 
(EMCDDA/Europol) and Risk Assessment on new psychoactive substances (EMCDDA)  
Performance indicator 6. Percentage of citizens’ perception of safety and security in 
relation to drug-related crime and violence and in terms of drugs, and perceived 
availability and accessibility, including online, of illicit drugs and new psychoactive 
substances (NPS) in Europe. (by age and gender) (two Eurobarometer studies in the 
beginning of 2021 and in 2025) 
Performance indicator 7. Percentage of population who use drugs currently (within last 
month), used drugs recently (within last year), and who have ever used (lifetime use) by 
drug and age group (EMCDDA General Population Survey)  
Performance indicator 8. Trends in the age of first use of illicit drugs based on school 
survey data taking into account the European School Survey Project on Alcohol and 
Drugs (ESPAD), the Health Behaviour in School-aged Children (HBSC) or other 
relevant studies, and, where applicable, the General Population Drug Use Survey 
(EMCDDA Key Epidemiological Indicator) 
Performance indicator 9: Trends in drug related morbidity and mortality. Composite 
EMCDDA reporting and barometer on the health impact of drug use. Covering analysis 
of the available data from both established and developing sources on: trends in drug 
related deaths, infectious diseases and behaviours associated health problems, including 




Performance indicator 10. Measures of availability of treatment and harm reduction 
services. Availability and coverage of opioid substitution treatment, availability of 
Needle and Syringe Programmes and coverage of HCV testing and treatment for drug 
injectors. (EMCDDA) 
Performance indicator 11. Member States with a comprehensive and balanced drugs in 
prisons policy - based on number of Member States with a balanced drugs strategy for 
prisons. (MS reporting)  
Performance indicator 12. Contribution to applicable 2030 Agenda for Sustainable 
Development Goals. (Eurostat annual monitoring report on the progress towards the 
SDGs in an EU context) 
 
